Recurrence scores may influence the kind of treatment that is recommended to estrogen receptor (ER)-positive/HER2-negative breast cancer patients who are being evaluated for first-line chemotherapy plus hormonal therapy (CT + HT), according to Swiss investigators.
The investigators, from various institutions, analyzed how patient data, which included the Oncotype DX multigene assay (ODX, Genomic Health) analysis, might affect the way the multidisciplinary Swiss tumor boards issued treatment